Interesting Images

Hepatocellular Carcinoma Microenvironment

Subjects: Oncology & Oncogenics View times: 27
Submitted by: Christo KOLE

Abstract

Despite progress in clinical research and therapy, Hepatocellular carcinoma (HCC) is one of one of the most frequent liver cancers and the fourth leading cause of cancer-related mortality worldwide. The hallmark of Immunotherapy as a novel treatment approach represent effective and promising option against several types of cancers including HCC which has led to encouraging results in terms of both safety and efficacy. This entry demonstrates and highlights the importance of tumor microenvironment as a predictive and prognostic marker and its clinical implications in immunotherapy response.

1. Introduction

Hepatocellular carcinoma (HCC) accounts for more than 80% of primary liver cancers[1]. HCC is one of the most frequent cancers and the fourth leading cause of cancer-related mortality worldwide[2] accounting for more than 800,000 deaths globally[3]. Moreover, in the next 10 years, more than one million patients are expected to die from liver cancer as estimated by the World Health Organization (WHO)[4]. The majority of HCC patients are males in a ratio of 2.4 to 1 compared to women[5]. Hepatitis B or C (HBV or HCV) is the most common risk factor, accounting for 80% of HCC cases globally[6]. Other factors that increase the risk of HCC are cirrhosis, alcohol abuse, environmental toxins, non-alcoholic fatty liver disease (NAFLD), metabolic diseases such as diabetes mellitus and obesity, smoking, and genetic and hereditary disorders[7][8].

The liver is considered an immune tolerant tissue, a characteristic that can be attributed to the particularities of its physiological function. Liver sinusoidal endothelial cells are exposed to a significant amount of bacterial antigens from portal circulation. These cells act as antigen-presenting cells (APCs) and regulate immunogenicity of liver microenvironment. Their role in normal liver function is to prevent acute response to bacterial agents in order to avoid unnecessary tissue damage[9]. As a result, liver sinusoidal endothelial cells express immunosuppressive molecules, such as programmed cell death ligand-1 (PD-L1). Another important cell type, Kupffer cells, are specialized liver-located macrophages that remove bacteria and produce immunosuppressive cytokines, such as IL-10 and prostaglandins[10]. They can also activate forkhead box P3 (FoxP3) in CD4+ T-cells resulting in proliferation of CD4+ regulatory T cells (Tregs), which negatively regulate immune response[11][12]. HCCs originate predominantly from hepatocytes and non-cancerous lesions (regenerative nodules and adenomas) from hepatic progenitor cells[13]. Increased PD-1 and PD-L1 expression has been observed in HCC patients[14][15], with the expression of PD-L1 associated with tumor aggressiveness and poor prognosis[16][17]. Among the molecular signaling pathways implicated in the pathogenesis of HCC, the Wnt/β-catenin signaling pathway is one of the most frequently activated[18]. Recent studies have shown that WNT/β-catenin signaling correlates with immune escape involving defective recruitment of dendritic cells by reducing CCL5 production and consequently impaired T-cell activity[19]. In addition, β-catenin activation promotes immune escape due to resistance to anti–PD-1 therapy in HCC[15][18][19]. Furthermore, high levels of Tregs in the HCC microenvironment are associated with poor prognosis. Dendritic cells (DCs), another type of APCs, also favor immune tolerance through the same mechanism[20]. Myeloid-derived suppressor cells (MDSCs) play a pivotal role in the development of immune tolerance through the expression of various cytokines (Figure 1), and their increased concentration in HCC tissues is linked to poorer prognosis[21][22]. For example, MDSCs promote tumor angiogenesis through vascular endothelial growth factor (VEGF) production and exert their immunosuppressive function through the induction of the CD4(+)CD25(+)Foxp3(+) Tregs[23][24]. MDSCs suppress natural killer (NK) cells, which limits the release of IFN-γ [25]. Moreover, immunosuppressive tumor-associated macrophages (TAMs) and tumor-associated neutrophils (TANs) impair CD8+ cytotoxic T lymphocytes (CTLs [26][27],while promoting accumulation and activation of CD4+CD25+Tregs[28]. Additionally, these cells express galectin-9, a ligand to TIM-3, an immune checkpoint protein expressed on Th1 cells surface. TIM3/galectin-9 pairing has a variety of effects on T-cells function, most often leading to suppression of immune response (Figure 1)[29] .

Cancers 12 02859 g001 550

Figure 1. Hepatocellular carcinoma microenvironment. (A) Tumor microenvironment creates a barrier from extracellular matrix for immunotherapy as well as for cytotoxic drugs to act significantly in HCC. (B) Resistance mechanisms in HCC inducing tumor progression, immunosuppression, and cancer cell survival. Activation of Wnt/CTNNB1 signaling inhibits CCL5 production, thereby DC recruitment. Hypoxia and activation of HIF-1a promotes recruitment of MDSCs, Tregs, and TANs, whereas HCV infection and MDSCs promote T-cell apoptosis through activation of TIM3 receptor by Galectin-9 secretion by monocytes. HCC: hepatocellular carcinoma cells; ECM: extracellular matrix; TAM: tumor-associated macrophages; ΤΑΝ: tumor-associated neutrophils; MDSCs: myeloid-derived suppressive cells; CTLs: cytotoxic T-lymphocytes; Tregs: CD4+ regulatory T cells; NKT cells: natural killer T cells; DC: dendritic cells IL: interleukin; TGF-β: transforming growth factor beta; IFNs: interferons; HiF1-a: hypoxia-inducible factor-1α; VEGF: vascular endothelial growth factor; CCL2: C-C motif chemokine ligand 2; CCL5: CC-chemokine ligand 5; CXCL12: C-X-C motif chemokine 12; CSF-1: colony stimulating factor 1; IFITM2: interferon-induced transmembrane protein 2.

Diagnosis of HCC in the early-stage offers a wide array of treatment options that increase overall survival (OS) and improve quality of life[30]. Unfortunately, due to late diagnosis, 70% to 80% of advanced HCC cases will not benefit from tumor resection[31]. Current treatment options for patients with unresectable HCC include transcatheter arterial chemoembolization (TACE) and the tyrosine kinase inhibitors sorafenib, regorafenib, and lenvatinib. These tyrosine kinase inhibitors are small molecules that inhibit multiple receptor tyrosine kinases implicated in tumor growth and angiogenesis, pathologic bone remodeling, drug resistance, and metastatic progression of cancer. HCC is a highly angiogenic tumor, thus inhibition of vascularization is a reasonable therapeutic strategy. Furthermore, inhibition of VEGF seems to enhance immunotherapy efficacy by exercising an immunomodulatory role in the tumor microenvironment. However, clinical benefit is still limited, and new therapeutic modalities are being explored[32][33][34].

Immunotherapy has proven to be effective and safe in treating a plethora of solid tumors, prolonging OS, and offering a tolerable toxicity profile[35][36][37]. Immunotherapy negates tumor-expressed extracellular ligands that suppress intrinsic immune response. Examples of such molecules are cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), programmed cell death protein-1 (PD-1), and its ligand, PD-L1. These proteins prevent T cells from recognizing and eliminating cancer cells[38]. This allows regular cells to avoid autoimmune destruction by downregulating T-cell activation. CTLA-4 competitively inhibits binding of B7 ligands to the co-stimulatory receptor CD-28, while PD-1 binds to PD-L1 and PD-L2 ligands, preventing T-cell activity in peripheral tissues[39]. Overexpression of PD-L1 has been detected in the microenvironment of several solid tumors, such as esophageal, colon, pancreatic, gastric, lung, breast[40], and HCC[41]. Checkpoint inhibitors are antibodies that activate T-cell mediated antitumor responses by selectively blocking the checkpoint receptors PD-1, PD-L1, and CTLA-4[42]. Targeting one or more of these receptors could mediate tumor regression in patients with melanoma, lung cancer, renal cell carcinoma, urothelial cancer, head and neck cancer, and other malignancies[43].

On the other hand, therapeutic cancer vaccines use a tumor-associated antigen (TAA) originating either from whole-cell tumor lysates and recombinant tumor peptides or full-length proteins or recombinant viruses encoding for TAAs. TAAs are transferred and presented by major histocompatibility complex (MHC) class I molecules in APCs to effectively induce activation of cytotoxic T-lymphocytes (CTLs)[44][45]. Another strategy in immune-regulated antitumor response is that of adoptive cell transfer (ACT). Immune cells are extracted from patients’ peripheral blood and undergo genetic engineering to express chimeric antigen receptors (CARs). These cell membrane proteins bind to specific cancer antigens stimulating immune destruction of tumor cells[46].

2. Hepatitis Infection and Immunotherapy

As previously mentioned, most cases of HCC are associated with chronic hepatitis infection. Thus, TME in HCC usually presents elements of chronic inflammation. Liver tissue in patients with HCC has a high concentration of CD8+ CTLs[47], however, they are suppressed and proliferate at a reduced rate. This T-Cell exhaustion is linked to overexpression of co-stimulatory molecules, such as B7-1 (CD80) and B7-2 on CD4+ T-cells and CD137 on CD8+ and NK cells. These molecules are vital points in the signaling of immune checkpoint pathways B7-CD28/CTLA-4 and PD-L1/PD-L2/PD-1[48]. This immunosuppressive TME prevents tumor antigen detection by DCs via suppression of TAA and MHC molecules through the expression of inhibitory molecules (IL-10, TGF-β, VEGF) (Figure 1)[49]. Other important extracellular ligands that suppress antitumor immune response are TIM-3 and LAG-3 proteins and mutated MHC type I receptors[50]. The existence of a high amount of exhausted CD8+ T-cells that overexpress negative co-stimulatory molecules, such as PD-L1, represents a clue for the use of ICIs in HCC. A high level of PD-L1 is also an adverse prognostic factor, thus increasing the need for effective treatment in this group of patients[51]. Several clinical trials have evaluated the safety and efficacy of anti-PD-L1 in HCC patients with hepatitis, though no data have been powered for statistical comparison. Predictive Biomarkers in HCC Immunotherapy.

Identification of patients’ subgroups that would benefit from ICI remains a mainstay goal of cancer research and several biomarkers have been explored in solid tumors. Apart from PD-1/PD-L1 expression, another common predictor of tumor response is microsatellite instability (MSI). MSI refers to random mutations occurring in small repetitive elements due to a defective (mismatch repair) MMR[52][53]. The accumulation of random mutations leads to increased neoantigen formation by the cells and target antigens for the immune system, promoting the expression of inflammatory cytokines and T-cell activation, thus rendering tumors susceptible to immunotherapy[54]. MSI high status (MSI-H) in HCC is rare, occurring in less than 3%[55][56][57][58][59]. Interestingly, another analysis, which included 122 patients with HCC, revealed no tumors displaying a typical MSI-H phenotype defined by PCR-based MSI testing[59]. Despite its rarity, inflammation-mediated dysfunction of the MMR pathway can contribute to the accumulation of mutations during hepatitis-associated tumorigenesis. Moreover, tumor mutational burden (TMB) analysis is useful as an agnostic histologic indicator to identify patients who can benefit from ICIs, and the use of PD-1 inhibitors is recommended in this setting as second or later line treatment[55].

On the other hand, genetic profiling of HCC using next-generation sequencing (NGS) has provided new opportunities to extensively analyze and identify those patients with HCC likely to benefit from targeted therapies[60]. High-resolution copy-number analysis and whole-exome sequencing has led to the identification of key genes, such as ARID1A, RPS6KA3, NFE2L2, IRF2 Wnt/β-catenin signaling pathway involvement in HCC tumors by oxidative stress metabolism and Ras/mitogen-activated protein kinase (MAPK) pathways[61]. Functional analyses showed tumor suppressor properties for IRF2, whose inactivation, exclusively found in HBV-related tumors, led to impaired TP53 function[61]. β-catenin is shown to support HCC cell survival during the earlier stages of HCC by promoting EGFR signaling[62] while upregulation of LEF-1, a key transcription factor of β-catenin, is found also in hepatitis B surface antigen (HBsAg)-expressing HCC cell[63][64]. In addition, Wnt signaling supports more discrete functions, such as escaping immune surveillance[18].

3. Conclusion

Despite advances in cancer treatment and translational research, HCC is still associated with inferior outcomes and high mortality. However, many clinical trials seek to evaluate the efficacy of immunotherapy in HCC, including ICIs, cancer vaccines, ACT, and combinations with chemoradiotherapy or other molecularly targeted agents, yielding some encouraging results. So far, immunotherapeutic strategies have been proved safe; however, studies of single ­agent ICIs failed to show a survival benefit compared to combination therapies. Importantly, combinations of immunotherapy with other modalities have resulted in better OS and PFS. The optimization of the best strategy remains challenging, mainly because of the low TMB and immune-suppressive environment on which HCC arises. Despite the encouraging results of a few MSI-H tumor cases which responded to immunotherapy, MSI-H phenotype seems to be a rare phenomenon in HCC. On the other hand, genetic profiling of HCC using NGS and identification of patients with HCC likely to benefit from immunotherapies, have shown promising results. Further analysis of NGS data will soon allow a better understanding of tumor heterogeneity and its potential role in treatment decision making by identifying HCC patients likely to benefit from immunotherapies. This is also supported by recent results in WNT/β-catenin association with immune evasion and resistance to anti-PD-1 therapy. Low number of mutations hampers the production and release of neo-antigens and subsequently leads to low number of TILs. Additionally, HCC immunosuppressive TME creates a significant barrier to the efficacy of immunotherapy agents. Further research needs to focus on overcoming immunotherapy resistance by targeting multiple immune defects using combinatorial approaches of immunotherapy and cytotoxic agents in patients with HCC.

The entry is from 10.3390/cancers12102859

References

  1. Ju Dong Yang; Pierre Hainaut; Gregory J. Gores; Amina Amadou; Amelie Plymoth; Lewis R. Roberts; A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nature Reviews Gastroenterology & Hepatology 2019, 16, 589-604, 10.1038/s41575-019-0186-y.
  2. Global Burden of Disease Cancer Collaboration; Christina Fitzmaurice; Christine Allen; Ryan M. Barber; Lars Barregard; Zulfiqar A. Bhutta; Hermann Brenner; Daniel J. Dicker; Odgerel Chimed-Orchir; Rakhi Dandona; et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015. JAMA Oncology 2017, 3, 524-548, 10.1001/jamaoncol.2016.5688.
  3. Zhuo, Y.; Chen, Q.; Chhatwal, J.; Hoshida, Y. Changing epidemiology of hepatocellular carcinoma and role of surveillance. In Hepatocellular Carcinoma: Translational Precision Medicine Approaches; Hoshida, Y., Ed.; Humana Press Cham: Totowa, NJ, USA, 2019; pp. 53–67
  4. World Health Organization. Projections of Mortality and Causes of Death, 2016 to 2060. Available online: http://www.who.int/healthinfo/global_burden_disease/projections/en/
  5. Hashem B. El-Serag; Hepatocellular Carcinoma. New England Journal of Medicine 2011, 365, 1118-1127, 10.1056/nejmra1001683.
  6. Hashem B. El-Serag; Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma. Gastroenterology 2012, 142, 1264-1273.e1, 10.1053/j.gastro.2011.12.061.
  7. Rawla, P.; Sunkara, T.; Muralidharan, P.; Raj, J.P. Update in global trends and aetiology of hepatocellular carcinoma. Współczesna Onkologia 2018, 22, 141–150.
  8. Villanueva, A. Hepatocellular carcinoma. N. Engl. J. Med. 2019, 380, 1450–1462.
  9. Craig N Jenne; Paul Kubes; Immune surveillance by the liver. Nature Immunology 2013, 14, 996-1006, 10.1038/ni.2691.
  10. Buonaguro, L.; Mauriello, A.; Cavalluzzo, B.; Petrizzo, A.; Tagliamonte, M. Immunotherapy in hepatocellular carcinoma. Ann. Hepatol. 2019, 18, 291–297.
  11. Schildberg, F.A.; Hegenbarth, S.I.; Schumak, B.; Scholz, K.; Limmer, A.; Knolle, P.A. Liver sinusoidal endothelial cells veto CD8 T cell activation by antigen-presenting dendritic cells. Eur. J. Immunol. 2008, 38, 957–967.
  12. Ormandy, L.A.; Hillemann, T.; Wedemeyer, H.; Manns, M.P.; Greten, T.F.; Korangy, F. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res. 2005, 65, 2457–2464.
  13. Tummala, K.S.; Brandt, M.; Teijeiro, A.; Graña, O.; Schwabe, R.F.; Perna, C.; Djouder, N. Hepatocellular carcinomas originate predominantly from hepatocytes and benign lesions from hepatic progenitor cells. Cell Rep. 2017, 19, 584–600.
  14. Kim, H.-D.; Song, G.-W.; Park, S.; Jung, M.K.; Kim, M.H.; Kang, H.J.; Yoo, C.; Yi, K.; Kim, K.H.; Eo, S.; et al. Association between expression level of PD1 by tumor-infiltrating CD8+ T cells and features of hepatocellular carcinoma. Gastroenterology 2018, 155, 1936–1950.e1917.
  15. Sia, D.; Jiao, Y.; Martinez-Quetglas, I.; Kuchuk, O.; Villacorta-Martin, C.; De Moura, M.C.; Putra, J.; Camprecios, G.; Bassaganyas, L.; Akers, N.K.; et al. Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features. Gastroenterology 2017, 153, 812–826.
  16. Jung, H.I.; Jeong, D.; Ji, S.; Ahn, T.S.; Bae, S.H.; Chin, S.; Chung, J.C.; Kim, H.C.; Lee, M.S.; Baek, M.-J. Overexpression of PD-L1 and PD-L2 is associated with poor prognosis in patients with hepatocellular carcinoma. Cancer Res. Treat. 2017, 49, 246–254.
  17. Calderaro, J.; Rousseau, B.; Amaddeo, G.; Mercey, M.; Charpy, C.; Costentin, C.; Luciani, A.; Zafrani, E.-S.; Laurent, A.; Azoulay, D.; et al. Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship with clinical and pathological features. Hepatology 2016, 64, 2038–2046.
  18. Harding, J.J.; Nandakumar, S.; Armenia, J.; Khalil, D.N.; Albano, M.; Ly, M.; Shia, J.; Hechtman, J.F.; Kundra, R.; El Dika, I.; et al. Prospective genotyping of hepatocellular carcinoma: Clinical implications of next-generation sequencing for matching patients to targeted and immune therapies. Clin. Cancer Res. 2018, 25, 2116–2126. [Google Scholar] [CrossRef]
  19. De Galarreta, M.R.; Bresnahan, E.; Molina-Sanchez, P.; Lindblad, K.E.; Maier, B.; Sia, D.; Puigvehí, M.; Miguela, V.; Casanova-Acebes, M.; Dhainaut, M.; et al. β-catenin activation promotes immune escape and resistance to anti-PD-1 therapy in hepatocellular carcinoma. Cancer Discov. 2019, 9, 1124–1141.
  20. Sachdeva, M.; Arora, S.K. Prognostic role of immune cells in hepatocellular carcinoma. EXCLI J. 2020, 19, 718–733.
  21. Kapanadze, T.; Gamrekelashvili, J.; Ma, C.; Chan, C.; Zhao, F.; Hewitt, S.; Zender, L.; Kapoor, V.; Felsher, D.W.; Manns, M.P.; et al. Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma. J. Hepatol. 2013, 59, 1007–1013.
  22. Zhou, J.; Liu, M.; Sun, H.; Feng, Y.; Xu, L.; Chan, A.W.H.; Tong, J.H.; Wong, J.; Chong, C.; Lai, P.B.S.; et al. Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy. Gut 2017, 67, 931–944.
  23. Hoechst, B.; Ormandy, L.A.; Ballmaier, M.; Lehner, F.; Krüger, C.; Manns, M.P.; Greten, T.F.; Korangy, F. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4+CD25+Foxp3+ T Cells. Gastroenterology 2008, 135, 234–243.
  24. Schrader, J. The role of MDSCs in hepatocellular carcinoma—In vivo veritas? J. Hepatol. 2013, 59, 921–923.
  25. Zhang, H.; Li, Z.; Wang, L.; Tian, G.; Tian, J.; Yang, Z.; Cao, G.; Zhou, H.; Zhao, L.; Wu, Z.; et al. Critical role of myeloid-derived suppressor cells in tumor-induced liver immune suppression through inhibition of NKT cell function. Front. Immunol. 2017, 8, 129.
  26. Zhou, J.; Ding, T.; Pan, W.; Zhu, L.-Y.; Li, L.; Zheng, L. Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients. Int. J. Cancer 2009, 125, 1640–1648.
  27. Michaeli, J.; Shaul, M.E.; Mishalian, I.; Hovav, A.-H.; Levy, L.; Zolotriov, L.; Granot, Z.; Fridlender, Z.G. Tumor-associated neutrophils induce apoptosis of non-activated CD8 T-cells in a TNFα and NO-dependent mechanism, promoting a tumor-supportive environment. Oncoimmunology 2017, 6, e1356965.
  28. Sharma, S.; Khosla, R.; David, P.; Rastogi, A.; Vyas, A.; Singh, D.; Bhardwaj, A.; Sahney, A.; Maiwall, R.; Sarin, S.K.; et al. CD4+CD25+CD127low regulatory T cells play predominant anti-tumor suppressive role in hepatitis B virus-associated hepatocellular carcinoma. Front. Immunol. 2015, 6.
  29. Li, H.; Wu, K.; Tao, K.; Chen, L.; Zheng, Q.; Lu, X.; Liu, J.; Shi, L.; Liu, C.; Wang, G.; et al. Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma. Hepatology 2012, 56, 1342–1351.
  30. Arii, S.; Yamaoka, Y.; Futagawa, S.; Inoue, K.; Kobayashi, K.; Kojiro, M.; Makuuchi, M.; Nakamura, Y.; Okita, K.; Yamada, R. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: A retrospective and nationwide survey in Japan. Hepatology 2000, 32, 1224–1229.
  31. El-Serag, H.B.; Rudolph, K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132, 2557-2576, doi:10.1053/j.gastro.2007.04.061.
  32. Buttner, N.; Schmidt, N.; Thimme, R. Perspectives of immunotherapy in hepatocellular carcinoma (HCC). Z Gastroenterol 2016, 54, 1334-1342, doi:10.1055/s-0042-120417.
  33. Llovet, J.M.; Ricci, S.; Mazzaferro, V.; Hilgard, P.; Gane, E.; Blanc, J.F.; de Oliveira, A.C.; Santoro, A.; Raoul, J.L.; Forner, A., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359, 378-390, doi:10.1056/NEJMoa0708857.
  34. Llovet, J.M.; Bruix, J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003, 37, 429-442, doi:10.1053/jhep.2003.50047.
  35. Schizas, D.; Charalampakis, N.; Kole, C.; Mylonas, K.S.; Katsaros, I.; Zhao, M.; Ajani, J.A.; Psyrri, A.; Karamouzis, M.V.; Liakakos, T. Immunotherapy for esophageal cancer: a 2019 update. Immunotherapy 2020, 12, 203-218, doi:10.2217/imt-2019-0153.
  36. Schizas, D.; Charalampakis, N.; Kole, C.; Economopoulou, P.; Koustas, E.; Gkotsis, E.; Ziogas, D.; Psyrri, A.; Karamouzis, M.V. Immunotherapy for pancreatic cancer: A 2020 update. Cancer Treat Rev 2020, 86, 102016, doi:10.1016/j.ctrv.2020.102016.
  37. Herzberg, B.; Campo, M.J.; Gainor, J.F. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. Oncologist 2017, 22, 81-88, doi:10.1634/theoncologist.2016-0189.
  38. Pardoll, D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012, 12, 252-264, doi:10.1038/nrc3239.
  39. Disis, M.L. Mechanism of Action of Immunotherapy. Seminars in Oncology 2014, 41, doi:10.1053/j.seminoncol.2014.09.004.
  40. Patel, S.P.; Kurzrock, R. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Mol Cancer Ther 2015, 14, 847-856, doi:10.1158/1535-7163.MCT-14-0983.
  41. Wang, B.J.; Bao, J.J.; Wang, J.Z.; Wang, Y.; Jiang, M.; Xing, M.Y.; Zhang, W.G.; Qi, J.Y.; Roggendorf, M.; Lu, M.J., et al. Immunostaining of PD-1/PD-Ls in liver tissues of patients with hepatitis and hepatocellular carcinoma. World J Gastroenterol 2011, 17, 3322-3329, doi:10.3748/wjg.v17.i28.3322.
  42. Rosenberg, S.A. Decade in review-cancer immunotherapy: entering the mainstream of cancer treatment. Nat Rev Clin Oncol 2014, 11, 630-632, doi:10.1038/nrclinonc.2014.174.
  43. Brower, V. Checkpoint blockade immunotherapy for cancer comes of age. J Natl Cancer Inst 2015, 107, doi:10.1093/jnci/djv069.
  44. Aranda, F.; Vacchelli, E.; Eggermont, A.; Galon, J.; Sautes- Fridman, C.; Tartour, E.; Zitvogel, L.; Kroemer, G.; Galluzzi, L. Trial Watch: Peptide vaccines in cancer therapy. . Oncoimmunology 2013, 2.
  45. Vacchelli, E.; Martins, I.; Eggermont, A.; Fridman, W.; Galon, J.; Sautès-Fridman, C.; Tartour E, Z.L.; Kroemer, G.; Galluzzi, L. Trial watch: Peptide vaccines in cancer therapy. Oncoimmunology 2012 1, 1557-1576.
  46. Akce, M.; Zaidi, M.Y.; Waller, E.K.; El-Rayes, B.F.; Lesinski, G.B. The Potential of CAR T Cell Therapy in Pancreatic Cancer. Front Immunol 2018, 9, 2166, doi:10.3389/fimmu.2018.02166.
  47. An, J.L.; Ji, Q.H.; An, J.J.; Masuda, S.; Tsuneyama, K. Clinicopathological analysis of CD8-positive lymphocytes in the tumor parenchyma and stroma of hepatocellular carcinoma. Oncol Lett 2014, 8, 2284-2290, doi:10.3892/ol.2014.2516.
  48. Chen, L.; Flies, D.B. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol 2013, 13, 227-242, doi:10.1038/nri3405.
  49. Makarova-Rusher, O.V.; Medina-Echeverz, J.; Duffy, A.G.; Greten, T.F. The yin and yang of evasion and immune activation in HCC. J Hepatol 2015, 62, 1420-1429, doi:10.1016/j.jhep.2015.02.038.
  50. Li, F.J.; Zhang, Y.; Jin, G.X.; Yao, L.; Wu, D.Q. Expression of LAG-3 is coincident with the impaired effector function of HBV-specific CD8(+) T cell in HCC patients. Immunol Lett 2013, 150, 116-122, doi:10.1016/j.imlet.2012.12.004.
  51. Sun, D.W.; An, L.; Huang, H.Y.; Sun, X.D.; Lv, G.Y. Establishing peripheral PD-L1 as a prognostic marker in hepatocellular carcinoma patients: how long will it come true? Clin Transl Oncol 2020, 10.1007/s12094-020-02390-y, doi:10.1007/s12094-020-02390-y.
  52. Lower, S.S.; McGurk, M.P.; Clark, A.G.; Barbash, D.A. Satellite DNA evolution: old ideas, new approaches. Curr Opin Genet Dev 2018, 49, 70-78, doi:10.1016/j.gde.2018.03.003.
  53. Veigl, M.L.; Kasturi, L.; Olechnowicz, J.; Ma, A.H.; Lutterbaugh, J.D.; Periyasamy, S.; Li, G.M.; Drummond, J.; Modrich, P.L.; Sedwick, W.D., et al. Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. Proc Natl Acad Sci U S A 1998, 95, 8698-8702, doi:10.1073/pnas.95.15.8698.
  54. Le, D.T.; Durham, J.N.; Smith, K.N.; Wang, H.; Bartlett, B.R.; Aulakh, L.K.; Lu, S.; Kemberling, H.; Wilt, C.; Luber, B.S., et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017, 357, 409-413, doi:10.1126/science.aan6733.
  55. Nakamura, Y.; Okamoto, W.; Shitara, K.; Kojima, T.; Morizane, C.; Naito, Y.; Yuki, S.; Kagawa, Y.; Narita, Y.; Nakashima, Y., et al. Large-scale analyses of tumor mutation burdens (TMBs) across various advanced gastrointestinal (GI) malignancies in the nationwide cancer genome screening project, SCRUM-Japan GI-SCREEN. Journal of Clinical Oncology 2018, 36, 12094-12094, doi:10.1200/JCO.2018.36.15_suppl.12094.
  56. Ang, C.; Klempner, S.J.; Ali, S.M.; Madison, R.; Ross, J.S.; Severson, E.A.; Fabrizio, D.; Goodman, A.; Kurzrock, R.; Suh, J., et al. Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma. Oncotarget 2019, 10, 4018-4025, doi:10.18632/oncotarget.26998.
  57. Kazachkov, Y.; Yoffe, B.; Khaoustov, V.I.; Solomon, H.; Klintmalm, G.B.; Tabor, E. Microsatellite instability in human hepatocellular carcinoma: relationship to p53 abnormalities. Liver 1998, 18, 156-161, doi:10.1111/j.1600-0676.1998.tb00143.x.
  58. Togni, R.; Bagla, N.; Muiesan, P.; Miquel, R.; O'Grady, J.; Heaton, N.; Knisely, A.S.; Portmann, B.; Quaglia, A. Microsatellite instability in hepatocellular carcinoma in non-cirrhotic liver in patients older than 60 years. Hepatol Res 2009, 39, 266-273, doi:10.1111/j.1872-034X.2008.00455.x.
  59. Goumard, C.; Desbois-Mouthon, C.; Wendum, D.; Calmel, C.; Merabtene, F.; Scatton, O.; Praz, F. Low Levels of Microsatellite Instability at Simple Repeated Sequences Commonly Occur in Human Hepatocellular Carcinoma. Cancer Genomics Proteomics 2017, 14, 329-339, doi:10.21873/cgp.20043.
  60. Dominguez, D.A.; Wang, X.W. Impact of Next-Generation Sequencing on Outcomes in Hepatocellular Carcinoma: How Precise Are We Really? J Hepatocell Carcinoma 2020, 7, 33-37, doi:10.2147/JHC.S217948.
  61. Guichard, C.; Amaddeo, G.; Imbeaud, S.; Ladeiro, Y.; Pelletier, L.; Maad, I.B.; Calderaro, J.; Bioulac-Sage, P.; Letexier, M.; Degos, F., et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet 2012, 44, 694-698, doi:10.1038/ng.2256.
  62. Kim, E.; Lisby, A.; Ma, C.; Lo, N.; Ehmer, U.; Hayer, K.E.; Furth, E.E.; Viatour, P. Promotion of growth factor signaling as a critical function of beta-catenin during HCC progression. Nat Commun 2019, 10, 1909, doi:10.1038/s41467-019-09780-z.
  63. Tian, X.; Zhao, C.; Ren, J.; Ma, Z.M.; Xie, Y.H.; Wen, Y.M. Gene-expression profiles of a hepatitis B small surface antigen-secreting cell line reveal upregulation of lymphoid enhancer-binding factor 1. J Gen Virol 2007, 88, 2966-2976, doi:10.1099/vir.0.83108-0.
  64. Tian, X.; Li, J.; Ma, Z.M.; Zhao, C.; Wan, D.F.; Wen, Y.M. Role of hepatitis B surface antigen in the development of hepatocellular carcinoma: regulation of lymphoid enhancer-binding factor 1. J Exp Clin Cancer Res 2009, 28, 58, doi:10.1186/1756-9966-28-58.

Related entries